Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study.

In the patient’s opinion, worry, bother and interference–related OAB symptoms, improved or showed a trend to greater improvement with higher dosing. 8 mg of fesoterodine provides also higher improvement in term of both patient-reported-treatment benefit and clinical global impression of change.

also in 53,322 other papers